Holen Sie sich die Stockscreener-App
1.56
70.59%
0.6455
Handel nachbörslich:
1.46
-0.10
-6.41%
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Needham cuts Neumora stock price target on navacaprant discontinuation By Investing.com - Investing.com Canada
Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy - Investing.com Canada
Neumora bins depression drug after Phase III failures - The Pharma Letter
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Asianet Newsable
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Benzinga
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc. - GlobeNewswire
Neumora plummets as phase 3 navacaprant data misses key goal - MSN
Neumora shifts focus to Alzheimer's and obesity drugs after navacaprant setback - The Business Journals
Neumora scraps depression drug development after repeated trial failures - Reuters
Neumora discards depression asset, lays off staffers after pair of late-stage flops - BioSpace
Neumora Therapeutics Discontinues Navacaprant After Phase 3 Failure, Advances Alzheimer’s and Schizophrenia Pipeline - Minichart
Neumora stock plunges after phase 3 trial failure By Investing.com - Investing.com South Africa
Navacaprant fails Phase 3 trials; Neumora halts its development, focusing on other drug candidates. - Pluang
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) - Yahoo Finance
Neumora pulls plug off depression drug after trial failures, cut jobs - Investing.com Canada
Neumora Ends Navacaprant After Phase 3 Trial Failure - TipRanks
Neumora discontinues navacaprant after phase 3 trial failures - Investing.com
Neumora discontinues navacaprant after phase 3 trial failures By Investing.com - Investing.com Canada
Neumora Therapeutics scraps depression drug after two late-stage trial failures - TradingView
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update - The Manila Times
Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline - Stock Titan
CRNX,NMRA Volatility & Greeks - Finviz
Neumora Therapeutics (NMRA) Slips Near Key Support; Oversold Conditions LoomMonthly Profile - newsline.com
Neumora Therapeutics advances pipeline for brain penetrant therapies in neurodegenerative and neuropsychiatric disease - Traders Union
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics commits to accelerating Alzheimer agitation therapies - Traders Union
Neumora Shareholders Approve Directors, Auditor and Executive Pay - The Globe and Mail
Neumora (NMRA) director and 10% owner receives 80,000 stock options at $1.86 - Stock Titan
NMRANeumora Therapeutics Inc. stock news, filings & ratings - Quantisnow
Neumora Therapeutics (NMRA) director granted 80,000 options at $1.86 - Stock Titan
Neumora Therapeutics (NMRA) director granted 80,000 stock options at $1.86 - Stock Titan
Neumora (NASDAQ: NMRA) director receives 80,000 stock options grant - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) investors approve directors, auditor and annual pay vote - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts - TipRanks
Number of shareholders of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Neumora Therapeutics (NMRA) Edges Lower as Stock Tests Key Support at $1.75Debt Free Companies - newsline.com
Neumora Therapeutics (NMRA) Slides 2.16% as Stock Tests Key Support LevelsRetail Driven Moves - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 Amid Mixed SentimentWyckoff Upthrust - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Consolidation ContinuesDividend Arbitrage - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue PhaseEBITDA Margin Trends - The Legal Advocate
Neumora Therapeutics (NMRA): Stock Holds Steady at $1.85 as Key Support and Resistance Levels TightenIV Crush Alert - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Disciplined SpendingEarnings Revision Report - newsline.com
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Stock Navigates Tight RangeTrader Community Signals - Newser
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Operational DisciplineLow Growth Earnings - Newser
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst - TipRanks
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
K2HV Equity reports 5.79M conversion shares for Neumora (NMRA) - Stock Titan
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target - TipRanks
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):